Woodline Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRX
Woodline Partners's EPRX Position: Q3 2026 in Review
Woodline Partners held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 746,864 shares worth $6.8M. The position accounts for 0.02% of the portfolio, ranked #647.
Woodline Partners first reported a position in EPRX in Q1 2026 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.
- Woodline Partners held 746,864 shares of Eupraxia Pharmaceuticals worth $6.8M as of Q3 2026.
- Woodline Partners left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
- Eupraxia Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q3 2026, its #647 holding.
- Woodline Partners first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.